Catalin Loghin.

Ted Feldman, M .D., Elyse Foster, M.D., Donald D. Glower, M.D., Saibal Kar, M.D., Michael J. Rinaldi, M.D., Peter S. Fail, M.D., Richard W. Smalling, M.D., Ph.D., Robert Siegel, M.D., Geoffrey A. Rose, M.D., Eric Engeron, M.D., Catalin Loghin, M.D., Alfredo Trento, M.D., Eric R. Skipper, M.D., Tommy Fudge, M.D., George V. Letsou, M.D., Joseph M. Massaro, Ph.D., and Laura Mauri, M.D. For the EVEREST II Investigators: Percutaneous Repair or Surgery for Mitral Regurgitation.

Somatostatin analogues,6,7 peptide-receptor radionuclide therapy,37,38 and inhibitors of the mammalian focus on of rapamycin39 show antitumor activity in pancreatic neuroendocrine tumors, and results from a phase 3 trial of everolimus are reported somewhere else in this problem of the Journal. 40 Our data present that rationally designed inhibition of PDGFR and VEGFR signaling with the use of sunitinib, given as a continuing daily dose, resulted in clinically meaningful improvements in progression-free survival, the objective-response price, and overall survival among patients with pancreatic neuroendocrine tumors.. Eric Raymond, M.D., Ph.D., Laetitia Dahan, M.D., Ph.D., Jean-Luc Raoul, M.D., Ph.D., Yung-Jue Bang, M.D., Ivan Borbath, M.D., Ph.D., Catherine Lombard-Bohas, M.D., Juan Valle, M.D., Peter Metrakos, M.D., C.M., Denis Smith, M.D., Aaron Vinik, M.D., Ph.D., Jen-Shi Chen, M.D.D., Pascal Hammel, M.D., Ph.D., Bertram Wiedenmann, M.D., Ph.D., Eric Van Cutsem, M.D., Ph.D., Shem Patyna, Ph.D., Dongrui Ray Lu, M.Sc., Carolyn Blanckmeister, Ph.D., Richard Chao, M.D., and Philippe Ruszniewski, M.D.: Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors Pancreatic neuroendocrine tumors are uncommon tumors arising from endocrine cells of the pancreas.1 Surgery may be the mainstay of treatment for resectable disease,2 and therapy directed to the liver may involve some palliative benefit for metastases that occur predominantly in the liver.3,4 Somatostatin analogues reduce symptoms resulting from hormone hypersecretion in functioning tumors and may delay disease progression in chosen sufferers.5-7 Streptozocin alone or in conjunction with doxorubicin remains the only chemotherapeutic agent approved for the treating advanced pancreatic neuroendocrine tumors,8-11 though the magnitude of benefit has been challenged.